Verdict No. 3031 · Search date 2026-09-08 · Methodology v1.0
Oral Nigella sativa seed powder plus omeprazole,
does it really help with Claimed equivalence to standard triple therapy for H. pylori eradication?
30-Second Summary
D
Evidence Grade D · 34 · Safety caution
Eradication was about 47.6% and 47.8% in the 1- and 3-g arms. Honey combinations are separate.
Composition varies by product and extraction method. People who are pregnant or breastfeeding, children, those with liver or kidney disease, and anyone using glucose-, blood-pressure-, anticoagulant-, antiseizure-, or immune-modifying medicines should seek clinical advice. Small trials cannot exclude rare or long-term harms.
What the
research showsGrade D with 34 points. Among completers, eradication was 66.7% (14/21) with 2 g plus omeprazole versus 82.6% (19/23) with triple therapy. Nonsignificance does not establish equivalence or replacement.
research showsGrade D with 34 points. Among completers, eradication was 66.7% (14/21) with 2 g plus omeprazole versus 82.6% (19/23) with triple therapy. Nonsignificance does not establish equivalence or replacement.
What the
ads claimAntibiotic replacement or equivalence requires a prespecified noninferiority margin and adequate sample size.
ads claimAntibiotic replacement or equivalence requires a prespecified noninferiority margin and adequate sample size.
Useful facts when choosing a product
- This verdict applies only to the exact plant part, formulation, route, dose, population, endpoint, and comparator shown above.
- Seed powder, fixed oil, aqueous extract, ethanolic topical preparation, purified thymoquinone, and combinations are not interchangeable.
- Composition varies by product and extraction method. People who are pregnant or breastfeeding, children, those with liver or kidney disease, and anyone using glucose-, blood-pressure-, anticoagulant-, antiseizure-, or immune-modifying medicines should seek clinical advice. Small trials cannot exclude rare or long-term harms.
Chamgap Semantic Classification Code
Permanent code issued
S.nigella-plus-omeprazole.oral.helicobacter-pylori-eradication.equivalent.activeSupplements and nutraceuticals > Nigella plus omeprazole > Oral > H. pylori eradication > Equivalence claim > Active triple therapy
The unproven equivalence intent remains encoded for retrieval; issuance is not endorsement of efficacy. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Nigella sativa plus omeprazole |
| Source or part used | Nigella sativa L. seed powder plus the medicine omeprazole |
| Formulation or processing | Seed-powder capsules plus proton-pump inhibitor |
| Route | Oral |
| Dose | 2 g/day seed powder plus 40 mg/day omeprazole; 1- and 3-g arms separate |
| Duration | Four-week treatment; stool antigen four weeks later |
| Population | Adults with H. pylori-positive nonulcer dyspepsia |
| Effect or condition | Eradication equivalent to standard triple therapy |
| Primary endpoint | Negative H. pylori stool antigen four weeks after treatment |
| Comparator | Clarithromycin, amoxicillin, and omeprazole triple therapy |
| Duplicate-detection key | nigella-plus-omeprazole|seed-powder-ppi|oral|adult-hpylori-nonulcer-dyspepsia|eradication-equivalence|4-weeks |
Gap Measurement · Verdict 3031 · D 34
What the research actually shows
Every Nigella arm also received omeprazole, and three powder doses were compared with triple therapy.
Why this is classified as D (34)
A clinical eradication endpoint and independent study are strengths, but E0, open alternate allocation, completer analysis, and no equivalence design yield D with 34 points.
Counterpoint. Uncertainty does not prove no effect, but a signal from one formulation cannot validate another formulation or claim.
Rejudgment record. Independent Codex cross-check — One page, one route, one population, one claim, one principal comparator
Scoring profile behind this grade
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Comparative study of Nigella sativa and triple therapy in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia | The cited controlled design and its allocation or masking limitations were independently checked. | 23 | Funding, product support, and employee authorship were assessed separately; unverified items were not counted as strengths. | The principal endpoint is defined in the exact facets; secondary outcomes remain separate. | The verified quantitative result is reported in the English reader answer and rationale without inventing missing confidence intervals. | Direct but not an equivalence trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Salem EM et al. Comparative study of Nigella sativa and triple therapy in eradication of Helicobacter pylori. Saudi J Gastroenterol. 2010. PMID: 20616418. PMCID: PMC3003218. DOI: 10.4103/1319-3767.65201.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Nigella Powder Plus Omeprazole for H. pylori—A Nonsignificant 2-g Contrast Does Not Prove Equivalence — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/oral-nigella-powder-omeprazole-helicobacter-pylori-eradication/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.